Inovio Pharmaceuticals (INO) Stock Statistics & Valuation Metrics

Inovio Pharmaceuticals has a market cap or net worth of $122.01M. The enterprise value is $61.11.

Inovio Pharmaceuticals has 103,397,514 shares outstanding. The number of shares has decreased by -2.65% in one year.

Inovio Pharmaceuticals’s return on equity (ROE) is -3.53 and return on invested capital (ROIC) is -259.45%.

The current PE Ratio of Inovio Pharmaceuticals is ―. Inovio Pharmaceuticals’s PEG ratio is 0.02.

In the last 12 months, Inovio Pharmaceuticals had revenue of 65.34K and earned -84.95M in profits. Earnings per share was -1.81.

In the last 12 months, operating cash flow was -39.68B and capital expenditures -195.40K, giving a free cash flow of -39.68B billion.

Inovio Pharmaceuticals pays an annual dividend of $0.069, resulting in a dividend yield of ―

Inovio Pharmaceuticals upcoming earnings date is Nov 10, 2026, TBA (Confirmed).

Inovio Pharmaceuticals as a current ratio of 1.40, with Debt / Equity ratio of 183.07%

In the past 12 months, Inovio Pharmaceuticals has paid 0.00 in taxes.

Inovio Pharmaceuticals EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -0.52.

Inovio Pharmaceuticals has $36.67M in cash and marketable securities with $8.00M in debt, giving a net cash position of $28.67M billion.

Gross margin is 0.00%, with operating margin of -132871.32%, and net profit margin of -130000.00%.

The average price target for Inovio Pharmaceuticals is $3.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy